TNFRSF4 and Alzheimer disease: Encouraging early-phase clinical trial outcomes for anti-OX40 antibodies (rocatinlimab and telazorlimab) and the anti-OX40L antibody (amlitelimab) in moderate to severe AD highlight the promise of targeting the OX40 pathway as an innovative treatment strategy for AD [13,14].